Glaxo CEO Expects Profit to Rise, Prepares for Split

The transcript discusses GSK's financial outlook, highlighting a 12-14% growth in earnings from its pharma and vaccines business. It outlines the company's R&D pipeline, with 64 assets and significant milestones in various medical fields. The discussion also covers the impact of the pandemic on oncology and healthcare, GSK's strategic shift towards vaccines and specialty medicines, and the company's plans to demerge into two entities. The focus on creating shareholder value and addressing concerns from Elliott Management is emphasized, with a commitment to future growth and innovation.

What strategic shift has GSK made regarding oncology?

What is GSK's priority regarding unsolicited offers?

How does GSK plan to create shareholder value during its separation?